The usefulness of placental alkaline phosphatase (PLAP) as a diagnostic marker of malignancy was assessed in pleural fluid from 60 patients with effusions. Pleural fluid PLAP activities were measured by an enzyme linked immunoassay (ELISA) using the two monoclonal antibodies H17E2 and H317. Similar values were found in groups of patients with primary bronchial tumours (n = 12), secondary malignancies (n = 23), and "benign" conditions (n = 25). The highest values were found in a small subgroup of patients with metastatic ovarian carcinoma. However, the production of this enzyme by normal lung makes the measurement of PLAP in pleural fluid unhelpful as a diagnostic aid to distinguish "benign" from malignant effusions. ( Clin Pathol 1992;45:1114- Placental-like alkaline phosphatase (PLAP) is an isoenzyme of the human syncytiotrophoblast which has been described in various cancer tissues as an oncodevelopmental protein3 and shows potential as a marker of ovarian cancer. 4 The enzyme has been found in normal lung3 and was first described in a patient with a primary bronchial carcinoma.
Pleural effusions are common in clinical practice and may be produced by a wide variety of pathological processes. Elucidating the precise aetiology of these effusions may be difficult, and protracted investigations may be required. It is often important to be able to discriminate "benign" from malignant effusions; but the use of conventional cytological techniques to detect malignant cells has a sensitivity of less than 60%.' 2 Attempts to improve this have included the measurement of pH, various biochemical variables, tumour associated antigens2 and antibodies' in pleural fluid. As yet no single technique with clinically useful specificity or sensitivity has emerged.
Placental-like alkaline phosphatase (PLAP) is an isoenzyme of the human syncytiotrophoblast which has been described in various cancer tissues as an oncodevelopmental protein3 and shows potential as a marker of ovarian cancer. 4 The enzyme has been found in normal lung3 and was first described in a patient with a primary bronchial carcinoma.
Methods
Samples of pleural fluid from 60 patients were studied. The patients were divided into three groups: 12 with primary bronchial carcinoma (four small cell, three squamous, two adenocarcinoma, two undifferentiated, one large cell), 23 with secondary tumour (seven breast, seven ovary, three lymphoma, three adenocarcinoma, two sarcoma, one leukaemia), and 25 with "benign" conditions (ten cardiac failure, three pneumonia, two rheumatoid, two empyema, one tuberculosis, one thromboembolism and six unknown). Patients in the "benign" group were followed up for one year to exclude any occult malignancy. The smoking habits of 52 of the 60 patients were noted. Samples (40-500 ml) of pleural fluid were taken to the laboratory without delay following aspiration. The fluid was centrifuged at 2000 rpm for 10 minutes and cytological preparations were made for diagnostic purposes. The supernatant fluid was stored in 20 ml aliquots at -40°C before PLAP activity was measured. Pleural fluid PLAP values were measured by an enzyme linked immunoassay4 (ELISA) using the two monoclonal antibodies HI 7E25 and H317.6 H17E2 recognises both PLAP and that which is produced by the lungs of smokers. H3 17 does not detect the latter. Statistical comparisons between groups were made using the Mann-Whitney U test. The correlation between the two assays was evaluated using Spearman's coefficient.
Results
The mean pleural PLAP activities for each group using the two different monoclonal antibodies are outlined in the table. There was no significant difference between activities seen in patients with "benign" or malignant effusions. There was a wide scatter of values in each group (figure). The small subgroup of patients with a pleural effusion from secondary ovarian cancer had higher activities of pleural PLAP, although this was not significant.
There was a close correlation between the two assays using the two monoclonal anti- 
